COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02638805
Recruitment Status : Completed
First Posted : December 23, 2015
Last Update Posted : November 5, 2018
Information provided by (Responsible Party):
Intarcia Therapeutics

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : October 2017
Actual Study Completion Date : October 2017
Certification/Extension First Submitted : October 30, 2018